MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today

Locations
Contact Us
Our Doctors
- Español
- عربى
- 中文
- Türkçe

Clear

close

Clear

MyChart

Donate Today

Locations
Contact Us
- Español
- عربى
- 中文
- Türkçe

Request an Appointment
New Patients
Current Patients
Referring Physicians

Patients & Family
Prevention & Screening
Donors & Volunteers
For Physicians
Research
Education & Training
Cancer Moonshots

Professional Education

CME/Conference Management

Online CME/Enduring Materials

Top

Jump To:

Back

CME/Conference Management

Online CME/Enduring Materials

MD Anderson is pleased to offer online learning opportunities for physicians and health care providers. These online CME programs range from communication skills to the latest advances in the field of oncology and come with specific instructions for completion and obtaining credit.

Other Sponsored Online CME Activities

Emerging Therapeutic Strategies for Relapse and Refractory Multiple Myeloma: Highlights from ASH 2018
This enduring panel discussion will review the efficacy and safety of emerging treatment options for patients with RRMM and discuss the clinical practice implications of these therapies in the context of currently approved therapies and treatment algorithms. This activity will also address practical strategies to individualize RRMM treatment paradigms, while considering both approved and investigational strategies, and accounting for patient-specific factors.

Optimizing the Use of Targeted Therapies into CLL Treatment Paradigms: Applying the Latest Evidence into Practice
This interactive activity features 2 leading experts in CLL who discuss and debate the latest advances regarding novel and emerging targeted therapies for patients with CLL, as well as discuss the evolving role of prognostic molecular biomarkers in targeted therapy initiation and treatment selection, highlighting key data presented at the 2018 Annual Meeting and Exposition of the American Society of Hematology (ASH).